Peptide purity requirements run from 50% crude material for screening to 98% for in vivo and structural work. This article explains the step-efficiency math that sets yield limits in solid-phase synthesis, the design choices that close the gap, and what a synthesizer must deliver to make a target…
Solid-phase peptide synthesis SPPS builds a peptide by anchoring the C-terminal residue to an insoluble resin and extending the chain one protected amino acid at a time. Each cycle consists of coupling the incoming amino acid to the free N-terminus and removing the temporary Fmoc protection group, with washes between steps clearing unreacted reagents and soluble by-products. Fmoc chemistry is the preferred route for most laboratories because the building blocks are inexpensive, widely available, and compatible with a broad range of side-chain modifications PMID 26785684 .
If every deprotection and coupling reaction went to completion, the resin would carry only full-length product. In practice no cycle is perfect, and the deficits accumulate in ways that determine both yield and purity.
The purity you actually need is set by the assay, not by what the synthesizer can deliver. The tiers below are the working conventions used across the industry. They are practical guidelines rather than regulatory cutoffs, and they apply to the purity of the peptide as measured by reversed-phase HPLC.
Why do these thresholds exist? Impurities interfere with assays in specific ways. Truncation sequences retain part of the target sequence and can compete with the full-length peptide for receptor or antibody binding, which corrupts binding measurements even when the truncated species is present at low level. Residual trifluoroacetic acid TFA from cleavage is cytotoxic and can kill cells in bioassays at concentrations that do not show up on a chromatogram. For drug substance work, residual TFA can be exchanged for acetate or citrate after synthesis, a salt-exchange step that matters when the final formulation or assay buffer cannot tolerate high TFA loads.
Two measurement caveats apply to every purity number you see. Reversed-phase HPLC integrates UV-absorbing peaks and mass spectrometry detects charged species, but neither method accounts for water or salts in the lyophilized powder. A sample reported as 95% pure by HPLC can contain a meaningful mass fraction of water and residual salts, so the actual peptide content can be lower than the chromatogram suggests. Amino acid analysis, which hydrolyzes the peptide and quantifies each amino acid, is the method normally used to establish the actual amount of peptide and therefore the true yield.
SPPS is a stepwise process, and the arithmetic of step efficiency is unforgiving. A peptide of n residues requires 2n deprotection and coupling steps. A 70-mer therefore requires 140 steps. If each step runs at 97% efficiency, the theoretical overall yield is 0.97^140, which is 1.4%. At 99% per step the overall yield rises to 24%. At 99.5% per step it reaches 50%. The difference between a routine and an optimized synthesis is not a few percentage points of final purity; it is the difference between recovering almost nothing and recovering half the theoretical material. These figures are ceilings. They assume no side reactions and no losses during cleavage and purification, so real recoveries are lower.
The most common impurities map to specific failure points in the cycle:
These impurities are not inert baggage. Because a deletion or truncation sequence shares much of the target's sequence, it can bind the same antibodies, receptors, or enzymes and distort the readout. That is why a purity tier is always paired with a question about which contaminants dominate. In an antigen preparation at 70%, the relevant question is whether the dominant impurity is a deletion sequence from a known difficult region, because that sequence, not the overall purity number, determines the antibody population induced.
The synthesis design decides whether a purity tier is reachable in one or two purification passes. The starting point is sequence analysis. Prediction software flags regions likely to aggregate, sequences longer than roughly 30 amino acids, hydrophobic stretches, and cyclic or branched architectures, all of which tend to break the assumptions of a routine protocol. Long peptides, generally those above 30 residues, accumulate step losses and are more likely to fold into aggregated, slowly coupling states on-resin.
Resin and linker are the first physical decisions. The standard core is polystyrene crosslinked with 1% divinylbenzene DVB , which swells well in the solvents used for Fmoc chemistry. Polyethylene glycol PEG derivatives are the main alternative; they are often promoted for difficult sequences because they reduce non-specific peptide-resin interactions, but the evidence base for a consistent crude-purity advantage over polystyrene-DVB is thin. The linker, attached to the resin bead, determines the C-terminal functional group of the final product: amide, carboxylic acid, or a protected handle for further derivatization. Choosing the linker is equivalent to choosing the C-terminus, so it must be decided before synthesis, not after.
Coupling reagent choice is a reactivity ladder. Faster synthesis workflows, where couplings are pushed to completion quickly, use more reactive reagents such as HCTU, HATU, and COMU. Slower workflows tolerate milder reagents such as DIC or HBTU. The trade-off is real: the most reactive reagents are also the least stable in solution, so they create more side products when left to stand or when used in large excess. Sterically hindered amino acids, such as those bearing bulky side chains or adjacent to proline, need a reagent reactive enough to acylate a hindered amine within the coupling window. Matching reagent reactivity to the steric demand of the sequence is therefore part of protocol design, and the same logic applies to temperature. Raising the reaction temperature accelerates couplings and can improve both speed and purity for some sequences, but the effect is sequence-dependent, and some peptides degrade or racemize faster at elevated temperature. Microwaves have no special effect on peptide synthesis beyond heating; the practice treats microwave irradiation as a convenient way to heat the vessel, not as a separate chemical force.
When prediction software flags a difficult region, the standard interventions are double coupling, extending coupling time, or increasing reagent equivalents. If a specific motif is the problem, pseudoprolines and dipeptide building blocks disrupt on-resin aggregation by temporarily breaking the backbone into a flexible unit; additives can suppress aspartimide formation; and alternative side-chain protection can remove a base-sensitive group that would otherwise be lost during deprotection. Capping permanently blocks unreacted amino groups after each coupling, either with acetic anhydride or a similar reagent. This prevents failed couplings from extending further, so the final product contains full-length peptide plus capped truncations rather than internal deletions. Because capped species are usually easier to separate by HPLC than deletion sequences of nearly identical mass, capping simplifies purification more than it simplifies the chromatogram itself.
Solvent handling is a quiet but decisive variable. Reusing solvents, even apparently clean ones, carries impurities and water into the reaction and measurably lowers peptide purity. Fresh solvents are not a refinement; they are a requirement for reproducible deprotection and coupling kinetics.
Real-time ultraviolet monitoring of the deprotection step gives the operator information during the run rather than after it. The deprotection effluent absorbs UV light in proportion to the Fmoc group removed; a plateau or a declining signal during the monitored window reveals incomplete deprotection at that cycle. In an automated system this can trigger an extended deprotection or a recouple, although the guidance for how to respond in real time is underdeveloped. What is clear is that monitoring converts a post-hoc purity failure into a detectable in-run event.
The instrument is the last and most expensive variable, and the features that matter map directly onto the chemistry above.
These are capabilities to test in a purchase evaluation, not brand claims. The practical question is whether the instrument can execute the protocol you designed, monitor the steps that can fail, and document the run in a way your downstream quality system accepts.
The published record establishes the core chemistry firmly. Fmoc SPPS is the preferred production method for peptides because of the quality and range of building blocks available PMID 26785684 , and detailed Fmoc SPPS protocols are available PMID 26424261; PMID 38997478 . Guidance for developing automated protocols, including modifications and troubleshooting, is available in the methods literature PMID 31879919 . The method is flexible enough to incorporate unusual residues: mono-ADP-ribosylated peptides were successfully made with an Fmoc-based approach using ADPr-glutamine, ADPr-asparagine, and ADPr-citrulline building blocks PMID 30097880 , and for sequence-defined hybrid peptides, stepwise solid-phase or solution assembly provides sequence control that polymerization methods lack PMID 35978269 . In short, the chemistry is mature, well documented, and adaptable.
What the literature does not establish is the precision of the purity tiers themselves. The thresholds above are industry conventions, and they are accepted because they match practical experience, not because a controlled study compared 85% versus 80% material in each assay type. There is no published head-to-head showing that a given application fails at 84% purity and passes at 86%. The right reading is that the tiers separate applications whose tolerance for impurity load is genuinely different, and they should be used as planning tools, not as pass-fail boundaries.
The same honesty applies to the open questions. There is no settled guidance on when a peptide should be stored freeze-dried versus in solution, and stability testing is still judged case by case. Which specific contaminants must be removed for a given application, even when the nominal purity tier is met, is answered by inspecting the impurity profile rather than by any general rule. The quantitative trade-off between fast, reactive coupling reagents and the side reactions their instability generates has not been measured across enough sequences to predict it in advance. Whether PEG-based resins improve crude purity for difficult sequences relative to polystyrene-DVB remains an open comparison. And the temperature-purity relationship, while real, has not been mapped onto sequence motifs with enough data to predict when heat helps and when it hurts.
The practical summary is short. Set the purity target from the assay and the tolerable contaminants from the sequence. Run the numbers on step efficiency so the yield expectation is honest. Design the synthesis around the difficult regions, choose the resin and linker for the C-terminus you need, match the coupling reagent to the steric demand and the schedule, cap to suppress deletions, use fresh solvents, and monitor deprotection in real time. Then pick an instrument that can run the design in parallel, document it, and dispense the expensive monomers without waste. The purity number you need is achievable if it was set before the first coupling was planned.
PMID 26424261 - Fmoc Solid-Phase Peptide Synthesis. Methods in Molecular Biology, 2015. https://pubmed.ncbi.nlm.nih.gov/26424261/
PMID 26785684 - Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science, 2016. https://pubmed.ncbi.nlm.nih.gov/26785684/
PMID 38997478 - Fmoc Solid-Phase Peptide Synthesis. Methods in Molecular Biology, 2024. https://pubmed.ncbi.nlm.nih.gov/38997478/
PMID 31879919 - Automated Solid-Phase Peptide Synthesis. Methods in Molecular Biology, 2020. https://pubmed.ncbi.nlm.nih.gov/31879919/
PMID 30097880 - ADPr-Peptide Synthesis. Methods in Molecular Biology, 2018. https://pubmed.ncbi.nlm.nih.gov/30097880/
PMID 35978269 - Advance in Hybrid Peptides Synthesis. Macromolecular Rapid Communications, 2022. https://pubmed.ncbi.nlm.nih.gov/35978269/
Related reading: Ab Biotechnology Cuts Costs with In-House Synthesis, Automated Peptide Synthesis: A Practical Getting-Started Guide, CordenPharma to Acquire AmbioPharm, Expanding Peptide API Capacity, Peptide Purification Bottlenecks and PEC 2.0 Solutions.